101 related articles for article (PubMed ID: 25298182)
41. Sequence analysis of meq oncogene among Polish strains of Marek's disease.
Woźniakowski G; Samorek-Salamonowicz E; Kozdruń W
Pol J Vet Sci; 2010; 13(2):263-7. PubMed ID: 20731180
[TBL] [Abstract][Full Text] [Related]
42. The oncogenic microRNA OncomiR-21 overexpressed during Marek's disease lymphomagenesis is transactivated by the viral oncoprotein Meq.
Stik G; Dambrine G; Pfeffer S; Rasschaert D
J Virol; 2013 Jan; 87(1):80-93. PubMed ID: 23055556
[TBL] [Abstract][Full Text] [Related]
43. Biocharacteristics shared by highly protective vaccines against Marek's disease.
Gimeno IM; Witter RL; Hunt HD; Reddy SM; Reed WM
Avian Pathol; 2004 Feb; 33(1):59-68. PubMed ID: 14681069
[TBL] [Abstract][Full Text] [Related]
44. In vivo expression patterns of microRNAs of Gallid herpesvirus 2 (GaHV-2) during the virus life cycle and development of Marek's disease lymphomas.
Zhao P; Li XJ; Teng M; Dang L; Yu ZH; Chi JQ; Su JW; Zhang GP; Luo J
Virus Genes; 2015 Apr; 50(2):245-52. PubMed ID: 25666057
[TBL] [Abstract][Full Text] [Related]
45. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
Baigent SJ; Smith LP; Nair VK; Currie RJ
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):78-86. PubMed ID: 16682084
[TBL] [Abstract][Full Text] [Related]
46. Marek's disease: an update on oncogenic mechanisms and control.
Venugopal K
Res Vet Sci; 2000 Aug; 69(1):17-23. PubMed ID: 10924389
[TBL] [Abstract][Full Text] [Related]
47. Molecular characterization of a Marek's disease virus strain detected in tumour-bearing turkeys.
Mescolini G; Lupini C; Davidson I; Massi P; Tosi G; Fiorentini L; Catelli E
Avian Pathol; 2020 Apr; 49(2):202-207. PubMed ID: 31702386
[TBL] [Abstract][Full Text] [Related]
48. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: selected biological and molecular characteristics.
Witter RL; Silva RF; Lee LF
Avian Dis; 1987; 31(4):829-40. PubMed ID: 2831870
[TBL] [Abstract][Full Text] [Related]
49. Asymmetric deletion of the junction between the short unique region and the inverted repeat does not affect viral growth in culture and vaccine-induced immunity against Marek's disease.
Sonoda K; Sakaguchi M; Matsuo K; Zhu GS; Hirai K
Vaccine; 1996 Mar; 14(4):277-84. PubMed ID: 8744553
[TBL] [Abstract][Full Text] [Related]
50. Hyperediting by ADAR1 of a new herpesvirus lncRNA during the lytic phase of the oncogenic Marek's disease virus.
Figueroa T; Boumart I; Coupeau D; Rasschaert D
J Gen Virol; 2016 Nov; 97(11):2973-2988. PubMed ID: 27655063
[TBL] [Abstract][Full Text] [Related]
51. Genome sequence determination and analysis of a Chinese virulent strain, LMS, of Gallid herpesvirus type 2.
Cheng Y; Cong F; Zhang YP; Li ZJ; Xu NN; Hou GY; Liu CJ
Virus Genes; 2012 Aug; 45(1):56-62. PubMed ID: 22476905
[TBL] [Abstract][Full Text] [Related]
52. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy.
Witter RL
Avian Dis; 1987; 31(4):752-65. PubMed ID: 2831867
[TBL] [Abstract][Full Text] [Related]
53. Oncogenic Marek's disease viruses lacking the 132 base pair repeats can still be attenuated by serial in vitro cell culture passages.
Silva RF; Gimeno I
Virus Genes; 2007 Jan; 34(1):87-90. PubMed ID: 16927124
[TBL] [Abstract][Full Text] [Related]
54. Production of Marek's disease vaccine.
Ben-Nathan D; Lustig S
Adv Biotechnol Processes; 1990; 14():347-65. PubMed ID: 2171556
[TBL] [Abstract][Full Text] [Related]
55. Interactions between Marek's disease virus Rispens/CVI988 vaccine strain and adenovirus field strain in chicken embryo fibroblast (CEF) cultures.
Niczyporuk JS; Woźniakowski G; Samorek-Salamonowicz E; Czekaj H
Pol J Vet Sci; 2014; 17(1):3-8. PubMed ID: 24724464
[TBL] [Abstract][Full Text] [Related]
56. Comparative 50% protective dose assays (PD50) of Marek's disease virus strain CVI988.
De Boer GF; Orthel FW; Krasselt M; Oei HL; Pereboom WJ; Barendregt LG
J Biol Stand; 1981 Jan; 9(1):15-22. PubMed ID: 6260810
[No Abstract] [Full Text] [Related]
57. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines.
King D; Page D; Schat KA; Calnek BW
Avian Dis; 1981; 25(1):74-81. PubMed ID: 6268052
[TBL] [Abstract][Full Text] [Related]
58. Comparative Molecular Characterization of Three
Kim T; Volkening JD; Spatz SJ
Avian Dis; 2020 Jun; 64(2):174-182. PubMed ID: 32550618
[TBL] [Abstract][Full Text] [Related]
59. Some aspects of lymphomagenesis of Marek's disease of chickens.
Nazerian K
Leukemia; 1988 Dec; 2(12 Suppl):198S-203S. PubMed ID: 2848997
[No Abstract] [Full Text] [Related]
60. Evolution of Marek's disease -- a paradigm for incessant race between the pathogen and the host.
Nair V
Vet J; 2005 Sep; 170(2):175-83. PubMed ID: 16129338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
